Answers are grounded in this paper and cite their sources.
Background: Genetic polymorphisms of metabolic enzymes, as well as a patient's sex, age, and individual susceptibility, affect the pharmacokinetics of propofol. Several reports show that polymorphisms of metabolic enzymes of propofol affect loss of consciousness during propofol anesthesia. We investigated whether genetic polymorphisms of the liver cytochrome P450 2B6 (CYP2B6), the main metabolic enzyme for propofol, and UDP-glucuronosyltransferase 1A9 (UGT1A9), as well as sex differences, affect the pharmacokinetics of propofol.
No takes yet. Share an insight, caveat, or question.
Kobayashi et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: